截至2025年6月13日收盘，白云山（600332）报收于26.76元，较上周的26.96元下跌0.74%。本周，白云 山6月10日盘中最高价报27.24元。6月13日盘中最低价报26.63元。白云山当前最新总市值435.06亿元， 在中药板块市值排名5/68，在两市A股市值排名307/5150。 本周关注点 广州白云山医药集团股份有限公司发布了2024年年度权益分派实施公告。主要内容如下：- A股每股现 金红利为人民币0.40元。- 股权登记日为2025年6月18日，除权（息）日和现金红利发放日均为2025年6 月19日。- 分红方案已经2025年6月3日的2024年年度股东大会审议通过，以方案实施前的公司总股本 1,625,790,949股为基数，每股派发现金红利人民币0.40元（含税），共计派发现金红利人民币 650,316,379.60元。- 无限售条件流通股的红利将委托中国结算上海分公司派发；广州医药集团有限公司 等特定股东的现金红利由公司直接发放。- 对于持有无限售条件A股股票的个人股东及证券投资基金， 实际每股派发现金红利人民币0.40元，暂不代扣代缴个人所得税。- 对于合格境外机构投资者（QF ...

廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）成員如下： 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 廣州白雲山醫藥集團股份有限公司 董事名單及彼等角色及職能 （一）執行董事：李小軍先生（董事長）、程寧女士（副董事長）、程洪進先生、唐和平先生與黎洪先 生；及 （二）獨立非執行董事：陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 註： C： 相關董事會委員會主任 M： 相關董事會委員會成員 中國廣州，2025年6月13日 2 董事會已成立四個委員會，下表為各董事會成員所屬委員會的成員資料： 委員會 董事 審核委員會 戰略發展與 投資委員會 提名與薪酬 委員會 預算委員會 程寧女士 M 黎洪先生 M 陳亞進先生 M M M C 黃民先生 M C M 黃龍德先生 C M 孫寶清女士 M M M 董事會 ...

一、董事离任情况 广州白云山医药集团股份有限公司（"公司"）董事会于2025年6月13 日收到公司副董事长杨军先生（"杨先生"）递交的书面辞职报告。杨先 生因工作调动原因，申请辞去公司第九届董事会副董事长、执行董事、董 事会战略发展与投资委员会主任及董事会提名与薪酬委员会委员职务。辞 职后，杨先生不再担任公司及公司附属企业的任何职务。 | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原 | 是否继续 在上市公 司及其控 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | 因 | 股子公司 | 毕的公开 | | | | | | | 任职 | 承诺 | | 杨军 | 副董事长、执行 董事、战略发展 | 2025 年 6 | 新一届董 事会成员 | 工作调 | 否 | 否 | | | 与投资委员会主 | 月 13 日 | 选举产生 | 动 | | | | | 任及提名与薪酬 | | 之日 | | | | | | 委员会委员 | | | | | | 二、离任对公司的影响 杨先生确认与公司董事会并无任何意见分歧，亦没 ...

白云山（600332）公告，公司董事会于2025年6月13日收到副董事长杨军先生的书面辞职报告。杨军先 生因工作调动，辞去副董事长、执行董事、战略发展与投资委员会主任及提名与薪酬委员会委员职务。 辞职后不再担任公司及附属企业任何职务。杨军先生确认与董事会无意见分歧，辞职未导致董事会成员 低于法定最低人数，不影响公司正常运作。杨军先生未持有公司股份，公司将及时补选董事。 ...

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has approved its 2024 annual equity distribution plan during the shareholders' meeting held on June 3, 2025, emphasizing its commitment to shareholder returns [1] Summary by Relevant Sections Equity Distribution Plan - The equity distribution plan includes a record date of June 18, 2025, and the ex-dividend date and cash dividend payment date are both set for June 19, 2025 [1] - The distribution is targeted at A-share shareholders registered with China Securities Depository and Clearing Corporation Limited in Shanghai as of the close of trading on the record date [1] Taxation Details - Individual shareholders and securities investment funds holding shares for over one year are exempt from personal income tax, while those holding for one month to one year are taxed at a rate of 10%, and those holding for less than one month are taxed at 20% [1] - Qualified Foreign Institutional Investors (QFII) and investors through the Shanghai-Hong Kong Stock Connect are subject to a 10% tax rate [1] Shareholder Engagement - The dividend plan reflects the company's focus on returning value to shareholders and aligns with relevant tax policy requirements [1] - Investors are advised to pay attention to the record date and tax treatment details to ensure the smooth realization of their rights [1]

证券代码：600332 证券简称：白云山 公告编号：2025-049 广州白云山医药集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利人民币0.40元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/18 | － | 2025/6/19 | 2025/6/19 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司 A 股股东。 本公司 H 股股东的现金红利发放的具体操作不适用本公告，具体可参阅本公司于 2025 年 6 月 3 日在香港联合交易所有限公司网站（https://www.hkexnews.hk/index_c.htm）发布的 关于 2024 ...

Core Viewpoint - Baiyunshan has received approval for the registration of Tadalafil tablets, positioning it as a successor to its existing product, Jin Ge (Sildenafil) [1][3]. Group 1: Product Overview - Tadalafil is a PDE5 inhibitor similar to Sildenafil, primarily used for treating erectile dysfunction (ED) [1][3]. - Tadalafil has advantages over Sildenafil, including lower dosage, longer half-life, and less impact from high-fat meals and alcohol [3]. Group 2: Market Dynamics - The domestic market for Tadalafil has not performed as well as Sildenafil, facing intense competition and a dual market structure of hospital and retail sales [3][4]. - In 2024, Tadalafil's sales in public hospitals were only RMB 186 million, indicating a limited market size [7]. - The introduction of centralized procurement policies has compressed the market ceiling for Tadalafil in hospitals [4]. Group 3: Competitive Landscape - In 2024, Tadalafil's total sales in hospitals were RMB 142 million, with the original drug, Cialis, holding a 30.14% market share, while generic competitors have gained significant volume [7][11]. - The retail market for Tadalafil is much larger, with total sales of approximately RMB 2.906 billion in 2024, split between offline and online pharmacies [14]. - The online retail market is highly fragmented, with various brands competing for market share [20]. Group 4: Challenges and Future Outlook - Baiyunshan faces challenges in establishing Tadalafil as a blockbuster product due to the competitive landscape and lack of first-mover advantage [23]. - The company is also exploring other male health medications, such as Dapoxetine, but the overall market for these products is limited [24]. - Jin Ge's sales and revenue have declined in 2024, indicating potential saturation in its market [24][25].

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

Group 1 - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration [1][2] - Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for treating erectile dysfunction (ED) [2] - The original manufacturer of Tadalafil is Eli Lilly, which received approvals in the EU and the US in November 2002 and November 2003, respectively, and in China in December 2004 [2] Group 2 - The company submitted the drug registration application for Tadalafil on January 2, 2024, and received acceptance on January 24, 2024 [2] - In 2024, the sales figures for Tadalafil tablets in Chinese public hospitals, urban pharmacies, and online pharmacies were approximately RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [2] - The company has invested approximately RMB 2.54 million and RMB 4.30 million in the R&D of 2.5mg and 5mg Tadalafil tablets, respectively [3] Group 3 - The approval of Tadalafil tablets enhances the company's product offerings in the male medication sector, potentially increasing its market competitiveness [3] - The company plans to commence production in accordance with relevant requirements and market demand [3]

Group 1 - Baiyunshan received drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration, indicating its entry into the erectile dysfunction treatment market [1] - Huayin Power plans to invest approximately 1.398 billion yuan in three renewable energy projects with a total installed capacity of 230 MW [2] - GAC Group reported a 24.8% year-on-year decline in May automobile sales, with total sales of 117,700 units [3] Group 2 - Honghui Fruits and Vegetables announced a potential change in control due to share transfer negotiations, leading to a temporary suspension of its stock and convertible bonds [4] - Fuyuan Pharmaceutical's subsidiary received a drug registration certificate for Bromhexine Hydrochloride oral solution, aimed at treating respiratory diseases [5][6] - Jianghan New Materials plans to repurchase shares worth 200 million to 400 million yuan, with a maximum price of 30 yuan per share [7][8] Group 3 - Sinan Navigation received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau due to multiple issues in its 2024 annual report [9][10] - Hesheng Co. received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [11] - Daqin Railway reported a 1.85% year-on-year decrease in cargo transportation volume in May, totaling 32.96 million tons [13] Group 4 - Ningbo Construction's subsidiary won a design and construction project with a bid of 787 million yuan [14] - Yuehongyuan A announced the termination of a major asset restructuring plan due to failure to reach an agreement on key terms [15][16] - Mingyang Smart Energy reached a 190 million yuan repurchase agreement with Haiji New Energy [18] Group 5 - CNE Group's subsidiary plans to reduce registered capital from 430 million yuan to 330 million yuan [19] - ST Baili received an administrative penalty for failing to disclose non-operating fund occupation matters, resulting in a fine of 4 million yuan [21] - Baichuan Co. completed the repurchase of a 7.14% stake in its subsidiary for 50 million yuan [22] Group 6 - Dongrui Co. reported May sales of 155,400 pigs, generating revenue of 203 million yuan, a decrease of 8.77% month-on-month [25][26] - Pengding Holdings reported a 22.43% year-on-year increase in May consolidated revenue, totaling 2.598 billion yuan [27] - Dabeinong reported May sales of 727,600 pigs, with total revenue of 1.248 billion yuan [28] Group 7 - Lihua Co. reported a 4.77% year-on-year decrease in May chicken sales revenue, totaling 1.118 billion yuan [29][30] - Jindan Technology plans to use up to 300 million yuan of idle funds for entrusted wealth management [31] - Youxunda won a project from the State Grid worth approximately 176 million yuan [33][34] Group 8 - Shenglan Co. received approval for its convertible bond issuance from the Shenzhen Stock Exchange [35][36] - Jingfang Technology's shareholder plans to reduce holdings by up to 2% of the company's shares [37] - Shiji Information's subsidiary signed a significant contract with Marriott for cloud services [39] Group 9 - Northeast Securities' subsidiary plans to terminate its listing on the New Third Board [40] - Yaji International's supervisor is under investigation for insider trading [42][43] - Yian Technology signed a strategic cooperation framework agreement with Shenzhen Hive Interconnect Technology [44] Group 10 - Jinyu Group's subsidiary acquired a real estate project for 3.364 billion yuan [46][47] - Kaiweite's major shareholder plans to reduce holdings by up to 3% of the company's shares [48] - Ningbo Energy's subsidiary plans to publicly transfer fixed assets valued at approximately 17.4372 million yuan [49]